Antisense oligonucleotides that inhibit expression of HIF-1

Details for Australian Patent Application No. 2004207576 (hide)

International Classifications

Event Publications

11 August 2005 PCT application entered the National Phase

PCT publication WO2004/066949 Priority application(s): WO2004/066949

3 April 2008 Assignment before Grant

Rexahn Corporation The application has been assigned to Rexahn Pharmaceuticals, Inc.

17 April 2008 Alteration of Name

The name of the applicant has been altered to Rexahn Pharmaceuticals, Inc.

23 October 2008 Application Accepted

Published as AU-B-2004207576

20 November 2008 Corrigenda

Applications Accepted - Name Index Under the name Rexahn Pharmaceuticals, Inc., Application No. 2004207576, under INID(31) correct the priopity details to 60/444,367 US 31 January 2003

19 February 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.